Tsai Chiao-Ling, Hsu Feng-Ming, Cheng Jason Chia-Hsien
Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (ROC); Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan (ROC).
Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (ROC).
Liver Cancer. 2016 Jul;5(3):210-20. doi: 10.1159/000367767. Epub 2016 May 10.
During the past two decades, external-beam radiation technology has substantially changed from traditional two-dimensional to conformal three-dimensional to intensity-modulated planning and stereotactic body radiotherapy (SBRT).
Modern techniques of radiotherapy (RT) are highly focused and capable of delivering an ablative dose to targeted hepatocellular carcinoma (HCC) tumors. SBRT is an option for selected patients with limited tumor volume and non-eligibility for other invasive treatments. Moreover, RT combined with a radiation sensitizer (RS) to increase the therapeutic ratio has shown promising results in select studies, prompting further investigation of this combination. With the undetermined role of RT in treatment guidelines and variation in patterns of treatment failure after RT in patient with HCC, useful biomarkers to guide RT decision-making and selection of patients are needed and emerging.
The objective of this review is to summarize the current RS with SBRT schemes and biomarkers for patient selection used to maximize the effect of RT on HCC.
在过去二十年中,外照射放疗技术已从传统的二维放疗大幅转变为适形三维放疗、调强放疗计划和立体定向体部放疗(SBRT)。
现代放疗(RT)技术高度聚焦,能够向靶向肝细胞癌(HCC)肿瘤给予消融剂量。SBRT是肿瘤体积有限且不适合其他侵入性治疗的特定患者的一种选择。此外,放疗联合放射增敏剂(RS)以提高治疗比在一些研究中已显示出有前景的结果,促使对这种联合治疗进行进一步研究。鉴于放疗在治疗指南中的作用尚未确定,且HCC患者放疗后治疗失败模式存在差异,因此需要并正在出现用于指导放疗决策和患者选择的有用生物标志物。
本综述的目的是总结当前用于SBRT方案的放射增敏剂以及用于患者选择的生物标志物,以最大限度地提高放疗对HCC的疗效。